Navigation Links
Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
Date:1/11/2012

BLUE BELL, Pa., Jan. 11, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is revolutionizing vaccines to fight cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will present an overview of the company at Noble Financials 8th Annual Equity Conference.

Noble Financial 8th Annual Equity Conference

January 17-18

Hollywood, FL

Hard Rock Hotel

 

Inovio Presentation

Tuesday, January 17

1:30 pm EST

Noble Financials 8th Annual Equity Conference Website

About Inovio Pharmaceuticals, Inc.

Inovio is developing its revolutionary vaccines to extend the profound medical benefits of the 20th century's immune-system-stimulating vaccines by preventing and treating today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and synthetic vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable synthetic vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the quarter ended September 30, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo: http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com


'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
2. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
5. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
6. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
7. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
9. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
10. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
11. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Partnering to fuel Philadelphia,s innovative ... Southeastern Pennsylvania (" Ben Franklin "); ... Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... million funding initiative over a four year period to ... a burgeoning economic vitality in digital health, Ben ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, ... escalation and expansion clinical trial for its lead drug candidate, AC0010, at the ... the trial was to determine the safety, antitumor activity, and recommended phase II ...
(Date:12/7/2016)... ... 07, 2016 , ... Huffman Engineering, Inc. , a ... Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based company recognized ... Integrator Partner certification gives customers confidence that our engineers are fully trained and ...
(Date:12/7/2016)... - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company focused ... for the treatment of cancer, today announced that ... Program with Cytovance Biologics ( Oklahoma City, ... product. Supported by recent positive interim clinical results ... cancer patients, OncoQuest has engaged Cytovance to establish ...
Breaking Biology Technology:
(Date:12/6/2016)... Dec. 6, 2016 Valencell , the leading ... has seen a third consecutive year of triple digit ... in 2016 with a 360 percent increase in companies ... increase was driven by sales of its wrist and ... in its technology for hearables for fitness and healthcare ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
Breaking Biology News(10 mins):